Navigation Links
ActX Launches a Genetic Medical Interpretation Service for 23andMe Customers

ActX has launched a medical genetic interpretation service for 23andMe customers. Using 23andMe raw data, easily available from 23andMe, customers can get access to professionally reviewed genetic screening similar to what a physician would order. This new service is available for both 23andMe Ancestry and Health + Ancestry customers.
With the ActX + 23andMe service, both 23andMe customers and their physicians receive access to a genetic profile with information about drug-genomic interactions, actionable hereditary risks and carrier status.

Physicians are able to see the genetic interpretation directly in their Electronic Health Record System, which includes real-time drug genomic interaction checking for efficacy and adverse reactions.

23andMe customers can see the medical interpretation in a smartphone application and on a portal.

23andMe customers can receive true precision medicine when their physician uses an integrated Electronic Health Record. For example, if a customer has a heart attack due to a blocked coronary artery, receives a coronary artery stent, and their physician then orders the typical stent associated prescription of Clopidogrel (Plavix), the prescription would be automatically checked against their genetics. If Clopidogrel is likely to be ineffective, their physician would be alerted prior to finishing the prescription and could pick another medication to help keep the stent open.

ActX adds checking for additional hereditary risks like Lynch Syndrome, which increases the risk of colorectal cancer. Before returning any hereditary risk, ActX confirms the result using a second test.

The ActX + 23andMe Service offers enhanced accuracy thanks to a validated, physician authorized, raw data interpretation performed by a College of American Pathologists (CAP) accredited laboratory. For serious genetic risks, we confirm the results using a different test (Sanger).

“Our service offers 23andMe customers a unique opportunity to take their 23andMe data and gain extensive medical information that will be useful to their physician.” said ActX CEO Andrew Ury. “By using only validated probes and Sanger confirmation for serious risks, we offer increased accuracy. We deliver medically relevant genetic information directly to the physician often built into the Electronic Health Record they already use”.

The 23andMe medical information is kept private and secure by ActX, following HIPAA privacy guidelines.

ActX is not affiliated with 23andMe. 23andMe is a trademark of 23andMe, Inc.

To learn more about the ActX + 23andMe service, visit

About ActX
ActX helps physicians make better decisions about medical treatment, using patients’ genetic information. ActX uses its GenoACT? clinical decision support program to analyze a patient’s genetic information and alert physicians in real time through their existing workflow tools (the Electronic Health Record) about drug-genome interactions, actionable hereditary risks and carrier status. For more information, visit, email or call (888) 998-2289.

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology news :

1. Earth Week: American U. launches William K. Reilly Fund for Environmental Governance & Leadership
2. University of Maryland Medical Center launches genetic-testing program for cardiac patients
3. Frontiers launches new open-access journal in Bioengineering and Biotechnology
4. Frontiers launches new open-access journal in physics
5. Elsevier launches new open access journal: Translational Proteomics
6. Elsevier launches open access journal: GeoResJ
7. Springer launches French- and Italian-language eBook collections
8. IriTech launches iris-recognition-based solutions for workforce and identity management
9. Running Website Run Research Junkie Launches to Analyze the Science Behind Running
10. Fluke Biomedical launches portable, feature-rich ProSim 3 and 2 Vital Signs Simulators
11. Clue, a Berlin Startup Founded By a Woman, Launches An Intelligent Tracking App That Decodes a Womans Fertility Cycle
Post Your Comments:
(Date:12/14/2019)... JOSE, Calif. (PRWEB) , ... December 12, 2019 ... ... sustainable agrochemical products that protect or enhance crop yields, has appointed Jean Pougnier ... strategic partners and establish relationships with go-to-market partners and influencers that will position ...
(Date:12/4/2019)... ... December 03, 2019 , ... ... and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, ... Inc. (“Ethicann”), a Calgary-based pharmaceutical company using botanically sourced cannabinoid oils to ...
(Date:12/4/2019)... ... December 04, 2019 , ... Cartessa Aesthetics ... Advanced Plasma Technology for U.S. dermatologists, plastic surgeons and licensed aesthetic providers. ... to employ LF technology – low frequency plus a patented wavelength and power ...
Breaking Biology News(10 mins):
(Date:12/31/2019)... ... ... At this year's SLAS conference, Visikol will present several talks on the ... culture , advanced imaging and multiplex analysis . Specifically, the Visikol ... inflammation and fibrosis as well as a 2D cell culture approach for ...
(Date:12/27/2019)... ... December 27, 2019 , ... Vici Health ... 505(b)(2) product pipeline that offers patients and healthcare providers options in the ... identified in collaboration with doctors and managed care professionals and developed at Vici’s ...
(Date:12/18/2019)... ... December 17, 2019 , ... Philadelphia IP law ... that it has hired Dr. Alia Orbin, Ph.D., J.D., an experienced registered patent ... preparation, filing and prosecution of patent applications related to pharmaceutical sciences, organic and ...
(Date:12/6/2019)... ... December 06, 2019 , ... ... 510(k) clearance for its latest CAPERE® Thrombectomy System for peripheral vascular, deep ... offers great benefits for first-in-line treatment for nonsurgical removal of soft emboli ...
Breaking Biology Technology: